TRACON Pharmaceuticals, Inc. (TCON)

Market Cap	82.82M
Revenue (ttm)	12.05M
Net Income (ttm)	-3.59M
Shares Out	45.50M
EPS (ttm)	-2.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,747
Open	1.830
Previous Close	1.810
Day's Range	1.740 - 1.840
52-Week Range	1.590 - 14.740
Beta	1.04
Analysts	Strong Buy
Price Target	60.00 (+3,196.7%)
Earnings Date	May 21, 2024

About TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 30, 2015
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: TCON

Analyst Forecast

According to 4 analysts, the average rating for TCON stock is "Strong Buy." The 12-month stock price forecast is $60.0, which is an increase of 3,196.70% from the latest price.

Price Target

$60.0

(3,196.70% upside)

Analyst Consensus: Strong Buy